8-K: Bakhu Holdings Secures $1.03 Million in Private Placement, Restructures Board and Debt

Bakhu Holdings closed the first tranche of a private placement, raising $1.03 million, while also restructuring its board and extending debt maturities.

Summary

• Bakhu Holdings, Corp. has completed the first tranche of a private placement, securing $1.03 million through the sale of secured promissory notes.
• These notes bear a 13% interest rate and are due in February 2028, with the option to be paid in cash or in kind.
• The company authorized a lead investor to seek up to $20 million in external funding through the sale of these convertible secured notes.
• The notes are secured by the company's assets and can be converted into common stock at $0.50 per share.
• Upon conversion, warrants will be issued with exercise prices ranging from $0.50 to $1.00 per share, depending on the tranche.
• A lead investor purchased $500,000 of the notes in this first tranche.
• Cell Science Holding Ltd. agreed to cancel its four outstanding shares of Series A Preferred Stock, eliminating its controlling voting power.
• The company's board will expand to seven directors, with three designated by the principal shareholder and three by the lead investor.
• The proceeds from the initial $1.03 million will be used to pay past due obligations, including $302,369 in compensation to officers and directors.
• Future proceeds will be used to reduce accounts payable, initiate insurance, pay professional fees, and for general working capital.

Sentiment

Score: 4

Explanation: The document indicates a company in a precarious financial position, relying on high-interest debt and using a significant portion of funds to pay past obligations. While there are some positive changes in governance, the overall sentiment is cautious due to the financial risks.

Positives

• The successful closing of Tranche I provides immediate capital of $1.03 million to address pressing financial obligations.
• The restructuring of the board of directors brings in experienced individuals from the biotechnology and cannabis industries.
• The extension of debt maturities to February 2028 provides the company with more financial flexibility.
• The cancellation of the Series A Preferred Stock simplifies the company's capital structure.
• The company has secured a lead investor who is also a principal shareholder, demonstrating confidence in the company's future.

Negatives

• The company is using a significant portion of the initial funding to pay past due obligations, including officer and director compensation.
• The company is relying on debt financing with a high interest rate of 13%, which could increase financial risk.
• The company's assets are pledged as security for the notes, which could limit future financial flexibility.
• The company is dependent on external funding to meet its financial obligations and execute its business plan.
• The company has a history of past due obligations, which may indicate underlying financial challenges.

Risks

• The company's reliance on debt financing with a 13% interest rate could strain its finances.
• The company's assets are pledged as security for the notes, which could limit future financial flexibility.
• The company's ability to raise the remaining $19 million in funding is not guaranteed.
• The company's success depends on its ability to execute its business plan and generate revenue.
• The company's financial health is dependent on the ongoing sale of notes to reduce past due accounts payable.

Future Outlook

The company intends to use additional proceeds from the ongoing sale of notes to reduce past due accounts payable, initiate officers and directors insurance, pay accrued and ongoing professional fees, general and administrative expenses, science engineering fees sublicensing related expenses, and for general corporate working capital.

Management Comments

• The board found a direct skills match with the Company's objectives to maximize its years of research and development and laboratory testing in cell replication technology and related proprietary equipment, processes and formulation to produce, manufacture and sell cannabis-related (cannabinoid) products.

Industry Context

The company is operating in the biotechnology and cannabis industries, which are both rapidly evolving and highly regulated. The appointment of directors with experience in these sectors suggests a strategic focus on these areas.

Comparison to Industry Standards

• The 13% interest rate on the secured promissory notes is relatively high, suggesting a higher risk profile compared to companies with lower borrowing costs.
• The conversion price of $0.50 per share is a key factor for investors, and its attractiveness will depend on the company's future performance and market conditions.
• The expansion of the board to include industry experts is a positive step, but the effectiveness of the new board will depend on their ability to guide the company's strategy and operations.
• The company's focus on cell replication technology and cannabis-related products aligns with current trends in the biotechnology and cannabis industries, but the company will need to demonstrate a competitive advantage to succeed.
• Compared to companies like Curaleaf Holdings, which acquired Grassroots Cannabis, Bakhu is still in an early stage of development and needs to establish a strong market presence.

Management Changes

Corporate Governance

Related Party Transactions

• The Lead Investor, John R. Munoz, is a principal stockholder and purchased $500,000 of the notes in Tranche I.
• Cell Science Holding Ltd., a related party, agreed to cancel its Series A Preferred Stock and extend the maturity date of its promissory note.

Stakeholder Impact

• Shareholders will see a change in the company's capital structure and board composition.
• Creditors will be paid down with the proceeds of the private placement.
• Employees may be impacted by the company's financial restructuring and operational changes.
• Customers and suppliers may be affected by the company's ability to execute its business plan.

Next Steps

• The company will continue to seek additional funding through the sale of convertible secured notes.
• The company will implement the board expansion and appoint new directors.
• The company will use the proceeds from the note sales to reduce past due accounts payable and fund operations.
• The company will work to develop and commercialize its cell replication technology and cannabis-related products.

Key Dates

Keywords

private placement, secured promissory notes, convertible notes, board of directors, debt restructuring, capital raise, cannabis, biotechnology, warrants, stock options